{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '10.3.3.', 'Other Analysis Sets', 'The PK population includes all randomized patients (safety population) who received cemiplimab', 'and who had at least 1 non-missing cemiplimab concentration following the first dose of', 'cemiplimab up to the end of the study.', 'The ADA analysis set includes all treated patients who received any study drug and had at least', '1 non-missing post-baseline ADA assay result following the first dose of study drug.', 'The biomarker analysis set includes all treated patients who had at least 1 sample assayed.', '10.4.', 'Statistical Methods', 'For continuous variables, descriptive statistics will include the following information: the number', 'of patients reflected in the calculation (n), mean, median, standard deviation, minimum, and', 'maximum. In addition, 25% percentile and 75% percentile may be provided if needed.', 'For categorical or ordinal data, frequencies and percentages will be displayed for each category.', 'The descriptive summary of time-to-event data will include median time to event and its 95% CI', 'using the Kaplan-Meier method.', '10.4.1.', 'Patient Disposition', 'The following will be provided:', 'The total number of screened patients: met the inclusion criteria regarding the target', 'indication and signed the ICF', 'The total number of randomized subjects: received a randomization number', 'The total number of patients in the FAS', 'The total number of patients in the SAF', 'The total number of patients who discontinued treatment and the reasons for treatment', 'discontinuation', 'The total number of patients who discontinued the study and the reasons for', 'discontinuation', 'A listing of patients treated but not randomized, patients randomized but not treated,', 'and patients randomized but not treated as randomized', 'A listing of patients prematurely discontinued from treatment and study, along with', 'reasons for discontinuation', '10.4.2.', 'Demography and Baseline Characteristics', 'Demographic and baseline characteristics will be summarized descriptively by treatment group', 'and by all patients combined.', 'Regeneron Pharmaceuticals, Inc.', 'Page 95 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '10.4.3.', 'Medical History', 'Medical history will be summarized by primary system organ class (SOC) and preferred term (PT)', 'for each treatment group, with the table sorted by decreasing frequency of SOC, followed by PT', 'based on the overall incidence between treatment groups.', '10.4.4.', 'Prior Medications/Concomitant Medications', 'Number and proportion of patients taking prior/concomitant medication will be summarized by', 'decreasing frequency of anatomical therapeutic chemical (ATC) level 2 and ATC level 4 according', 'to the current version of the World Health Organization Drug Dictionary, based on the overall', 'incidence between treatment groups.', 'Listings of pretreatment medication and concomitant medications include generic name, ATC', 'levels 2 and 4, indication, study day onset, the study end date (defined similarly as for study onset', 'day), ongoing status, dose, frequency, and route.', 'For medications started before treatment, the study day onset is defined as date of medication start', '- date of the first dose; for medications started on or after treatment, the study day onset is defined', 'as the date of medication start - date of the first dose + 1.', '10.4.5.', 'Efficacy Analyses', '10.4.5.1. Primary Efficacy Analysis', 'The primary analysis of os will be implemented after the pre-specified numbers (Table 15) of', 'os events have been reported in patients with SCC. The analyses will include all survival', 'information available at the time.', 'The primary endpoint of os will be analyzed in SCC patients first by stratified log-rank test using', 'geographic region (North America versus Asia-Pacific versus ROW) as a stratification factor.', 'The HR and its 95% CI will be estimated by a stratified Cox regression model using the treatment', 'as covariate.', 'If the analysis of os is statistically significant in the SCC patients, then the analysis of os will be', 'performed in the overall population by stratified log-rank test using the following stratification', 'factors:', '1. Histology: SCC versus adenocarcinoma. Adenosquamous histology will be considered', 'adenocarcinoma for the purpose of stratification.', '2. Geographic Region: North America versus Asia Pacific versus ROW.', 'The HR and its 95% CI will be estimated by a stratified Cox regression model using the treatment', 'as covariate.', '10.4.5.2. Secondary Efficacy Analysis', 'The multiplicity is controlled by a hierarchical testing procedure as follows: The primary endpoint', 'OS will be tested in SCC patients first. If statistically significant, os will be tested in the overall', 'population. If statistically significant, the secondary endpoints PFS and ORR will be tested. The', 'Regeneron Pharmaceuticals, Inc.', 'Page 96 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}